In recent years, against a backdrop of geopolitical uncertainty and market volatility, Switzerland's biotech sector has delivered continued growth, powered by innovation, talent, and tenacity. Annual growth rates of around 5% have been supported by sustained levels of R&D investments, record funding, and accelerated startup creation by venture builders.

In a scientific and geopolitical environment that is evolving at unprecedented speed, Swissmedic's role increasingly requires building bridges: between innovators and regulators, between research discoveries and their safe application, between approved therapies and the patients who rely on them, and between global standards and domestic expectations.

Biotechnology — drawing on the versatility, precision, and efficiency of biological systems — offers powerful tools to emulate nature's principles across a wide range of industries, far beyond pharmaceuticals and advanced therapeutics. Switzerland's success in attracting the talent capable of driving a transition from unsustainable to sustainable manufacturing will help to achieve its goal of

Swiss-based scientists Christian Klein and Pablo Umaña have been working closely together for over 20 years and are distinguished by both the number and quality of their inventions in biotechnology. The following interview provides insights from the perspective of this biotech inventor dream team. Their shared area of interest is antibodies for immunotherapy, with a focus on bi- and multispecific

A strong biotech industry needs qualified personnel to develop the innovations for tomorrow's society. The Swiss National Science Foundation (SNSF) empowers today's young researchers to develop their own ideas. By investing in talent development, it contributes to Switzerland's competitiveness and adaptability in a rapidly changing world.